CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 188 enrolled
Drug / intervention
180mg of ETC-1002(bempedoic acid) +3 moredrug
Likely dose
180mg of ETC-1002(bempedoic acid)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04784442
NCT04784442Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Mar 5, 2021·Updated May 10, 2024

In Brief

A Phase 2 clinical trial evaluating 180mg of ETC-1002(bempedoic acid), 120mg of ETC-1002(bempedoic acid), and 2 other interventions for Hypercholesterolemia. Completed, enrolled 188 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg versus placebo added to ongoing stable statin therapy or other lipid-modifying therapies in Japanese patients with hypercholesterolemia treated for 12 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedMar 5, 2021
Enrollment StartMar 24, 2021
Primary CompletionApr 18, 2022
Study CompletionMay 17, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.3 years ago

Interventions

180mg of ETC-1002(bempedoic acid)drug

180mg, tablet, once daily, for 12 weeks

120mg of ETC-1002(bempedoic acid)drug

120mg, tablet, once daily, for 12 weeks

60mg of ETC-1002(bempedoic acid)drug

60mg, tablet, once daily, for 12 weeks

Placebodrug

placebo, tablet, once daily, for 12 weeks